Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome

Shuichi Ito(Yokohama City University), Tomoya Kaneda(Tokyo Medical and Dental University), Akira Ishiguro(National Center For Child Health and Development), Misaki Akiyama(National Center For Child Health and Development), Yuta Inoki(Kobe University), Kentaro Nishi(National Center For Child Health and Development), Kenji Ishikura(Kitasato University), Kei Osaka(National Center For Child Health and Development), Koichi Kamei(National Center For Child Health and Development), Masao Ogura(Hokkaido University Hospital), Mai Sato(Kyoto University)
Pediatric Nephrology
January 25, 2024
10.1007/s00467-023-06270-9
Cited by 3

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135